$925,34
+$21,35(+2,36%)
*Data last updated: 2026-04-17 19:53 (UTC+8)
As of 2026-04-17 19:53, Eli Lilly & Co. (LLY) is priced at $925,34, with a total market cap of $853,57B, a P/E ratio of 46,76, and a dividend yield of 0,68%. Today, the stock price fluctuated between $919,06 and $930,00. The current price is 0,68% above the day's low and 0,50% below the day's high, with a trading volume of 2,01M. Over the past 52 weeks, LLY has traded between $623,78 to $1.133,95, and the current price is -18,39% away from the 52-week high.
LLY Key Stats
Yesterday's Close$905,03
Market Cap$853,57B
Volume2,01M
P/E Ratio46,76
Dividend Yield (TTM)0,68%
Dividend Amount$1,73
Diluted EPS (TTM)22,98
Net Income (FY)$20,63B
Revenue (FY)$65,17B
Earnings Date2026-04-30
EPS Estimate7,07
Revenue Estimate$17,59B
Shares Outstanding943,14M
Beta (1Y)0.504
Ex-Dividend Date2026-02-13
Dividend Payment Date2026-03-10
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
SectorHealthcare
IndustryDrug Manufacturers - General
CEODavid A. Ricks
HeadquartersIndianapolis,IN,US
Official Websitehttps://www.lilly.com
Employees (FY)50,00K
Average Revenue (1Y)$1,30M
Net Income per Employee$412,76K
Eli Lilly & Co. (LLY) FAQ
What's the stock price of Eli Lilly & Co. (LLY) today?
x
Eli Lilly & Co. (LLY) is currently trading at $925,34, with a 24h change of +2,36%. The 52-week trading range is $623,78–$1.133,95.
What are the 52-week high and low prices for Eli Lilly & Co. (LLY)?
x
What is the price-to-earnings (P/E) ratio of Eli Lilly & Co. (LLY)? What does it indicate?
x
What is the market cap of Eli Lilly & Co. (LLY)?
x
What is the most recent quarterly earnings per share (EPS) for Eli Lilly & Co. (LLY)?
x
Should you buy or sell Eli Lilly & Co. (LLY) now?
x
What factors can affect the stock price of Eli Lilly & Co. (LLY)?
x
How to buy Eli Lilly & Co. (LLY) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
